FY2024 Earnings Estimate for CGTX Issued By B. Riley

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – B. Riley issued their FY2024 EPS estimates for shares of Cognition Therapeutics in a research report issued on Tuesday, November 26th. B. Riley analyst M. Mamtani forecasts that the company will post earnings per share of ($0.62) for the year. B. Riley currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.93) per share. B. Riley also issued estimates for Cognition Therapeutics’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.25) EPS and Q4 2025 earnings at ($0.27) EPS.

Several other brokerages also recently weighed in on CGTX. Chardan Capital reissued a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Cognition Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Cognition Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Cognition Therapeutics Price Performance

Cognition Therapeutics stock opened at $0.40 on Thursday. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95. The company’s 50-day moving average is $0.47 and its 200 day moving average is $1.12. The firm has a market capitalization of $16.53 million, a P/E ratio of -0.41 and a beta of 1.34.

Institutional Trading of Cognition Therapeutics

Hedge funds have recently bought and sold shares of the stock. CM Management LLC boosted its holdings in shares of Cognition Therapeutics by 14.3% in the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after buying an additional 25,000 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its position in shares of Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares in the last quarter. Sigma Planning Corp lifted its holdings in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Cognition Therapeutics in the 3rd quarter worth $27,000. Finally, Bangor Savings Bank grew its stake in Cognition Therapeutics by 41.6% during the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock worth $56,000 after buying an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.